T. Rowe Price Associates’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $35.9M | Sell |
|
|||||
|
2025
Q1 | $74.1M | Sell |
|
|||||
|
2024
Q4 | $79.8M | Buy |
|
|||||
|
2024
Q3 | $79.8M | Sell |
|
|||||
|
2024
Q2 | $110M | Sell |
|
|||||
|
2024
Q1 | $117M | Buy |
|
|||||
|
2023
Q4 | $53M | Buy |
|
|||||
|
2023
Q3 | $29.7M | Sell |
|
|||||
|
2023
Q2 | $38.1M | Buy |
|
|||||
|
2023
Q1 | $850K | Buy |
|
|||||
|
2022
Q4 | $786K | Sell |
|
|||||
|
2022
Q3 | $711K | Buy |
|
|||||
|
2022
Q2 | $458K | Sell |
|
|||||
|
2022
Q1 | $630K | Buy |
|
|||||
|
2021
Q4 | $567K | Buy |
|
|||||
|
2021
Q3 | $220K | Hold |
|
|||||
|
2021
Q2 | $287K | Buy |
|
|||||
|
2021
Q1 | $287K | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $20.8M | Sell |
|
|||||
|
2020
Q2 | $42.3M | Buy |
|
|||||
|
2020
Q1 | $38.6M | Sell |
|
|||||
|
2019
Q4 | $58.2M | Sell |
|
|||||
|
2019
Q3 | $37.4M | Buy |
|
|||||
|
2019
Q2 | $37.3M | Buy |
|
|||||
|
2019
Q1 | $10M | Buy |
|
|||||
|
2018
Q4 | $6.31M | Buy |
|